Top Story

Extended anticoagulation beneficial after pulmonary embolism; stops when treatment ends

July 7, 2015

Patients who experience a first pulmonary embolism may benefit from anticoagulation therapy for up to 2 years after the unprovoked episode, although the benefits of treatment do not appear to continue after therapy is stopped, the results of study findings in the Journal of the American Medical Association show.

An initial pulmonary embolism not preceded by a transient risk factor such as surgery may “require long-term secondary prevention measures” to reduce the risk for additional blood clots or major bleeding, with the lack of an inciting risk factor putting patients at “a much higher risk of recurrence,” according to researchers.

In the Journals

Daytime traffic noise exposure may raise mortality risk

July 7, 2015
Long-term exposure to a greater amount of road traffic noise was associated with a small but significant increased risk for mortality and stroke-related hospitalization…
Trial Scorecards

Trial Scorecard: EXACT-HF

Cardiology Today, July 2015
Study of effectiveness of allopurinol for relieving symptoms in patients with HF and high blood uric acid levels.
FDA NewsPublication Exclusive

FDA advisory panel backs approval of PCSK9 inhibitors

Cardiology Today, July 2015
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted in June to recommend approval of two PCSK9 inhibitors for the reduction of LDL in certain…
Trial Scorecards

Trial Scorecard: VADT

Cardiology Today, July 2015
Researchers assessed whether tight control of HbA1c in veterans with diabetes is associated with improved CV outcomes.
More News Headlines »
CME
Antiplatelet Agents in ACS Distinguishing Characteristics Safety and Efficacy

Antiplatelet Agents in ACS: Distinguishing Characteristics, Safety, and Efficacy

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
Meeting News Coverage Video
VIDEO: Knowledge of supplements and drug interactions essential for HF practitioners

VIDEO: Knowledge of supplements and drug interactions essential for HF practitioners

June 28, 2015
NEW ORLEANS – Joseph Ho, PharmD, clinical pharmacist with Ochsner Baptist Medical Center in New Orleans…
More »
Antiplatelet Therapy in ACS and PCI

Antiplatelet Therapy in ACS and PCI

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
morganatic-roan